Q-omics provides the consensus-scored MAP1S profile across patient tissues and cancer cell-line models. MAP1S expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MAP1S is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MAP1S protein abundance shows 23,047 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SCLC, KIRC, and HNSC as cancer lineages where MAP1S shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP1S — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP1S survival associations across molecular data types. MAP1S RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP1S RNA expression–survival associations across cancer types. High MAP1S expression shows unfavorable associations in ACC, KIRP, BLCA, LIHC and LUSC, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MAP1S RNA expression.
This table summarizes MAP1S tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP1S. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP1S shows higher tumor expression in KIRC, KIRP, COAD, LIHC, HNSC and STAD. The KIRC box plot shows higher MAP1S RNA expression in tumor versus normal tissue (log2 FC = +0.830, t-test p < 0.001).
This table shows molecular features associated with MAP1S in patient tissues and cancer cell lines. In patient samples, MAP1S shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP1S RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
